Featured here, the Income Statement (earnings report) for Relmada Therapeutics Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses ...

Explore the detailed Summit Therapeutics PLC balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...

Explore the detailed Axsome Therapeutics Inc balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...

US Dollar Forecast: Will DXY Break 110? Tariffs and PMI Data Set the Tone – GBP/USD and EUR/USD OutlookMon, 03 Feb 2025 08:12:29 GMT Gold (XAU) Silver (XAG) Daily Forecast: Strong Dollar and ...

On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in biological products trading at $1.93 per share, announced the upcoming departure of Timothy Moore, an executive officer ...

Investing.com -- Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its DisTinGuish study of sirexatamab combined with tislelizumab and ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, announced significant preclinical results for their new drug candidate ...

DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical ...

Investing.com -- Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...